Posted by Michael Wonder on 13 Mar 2023
Harrow announces transitional pass through reimbursement status for Iheezo (chloroprocaine hydrochloride 3% ophthalmic gel)
13 March 2023 - Harrow today announced that the Centers for Medicare & Medicaid Services has approved transitional pass-through reimbursement status for Iheezo (chloroprocaine hydrochloride 3% ophthalmic gel) which is indicated for ocular surface anaesthesia.
Beginning 1 April 1 2023, and for the three years thereafter, Iheezo will be eligible for separate reimbursement outside of the surgical bundled payment in both the Ambulatory Surgery Center and Hospital Outpatient Department settings of care.
